Matthew Scaramozza
About
Matthew Scaramozza is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology.
According to data from OpenAlex, Matthew Scaramozza has authored 22 papers receiving a total of 515 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 8 papers in Oncology and 4 papers in Neurology. Recurrent topics in Matthew Scaramozza's work include Multiple Sclerosis Research Studies (13 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers) and Peripheral Neuropathies and Disorders (3 papers). Matthew Scaramozza is often cited by papers focused on Multiple Sclerosis Research Studies (13 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers) and Peripheral Neuropathies and Disorders (3 papers). Matthew Scaramozza collaborates with scholars based in United States, Switzerland and Germany. Matthew Scaramozza's co-authors include Hans-Peter Hartung, Patrick Vermersch, Patricia K. Coyle, Thomas Leist, Bruce Cree, Mark S. Freedman, Giancarlo Comi, Florence Casset‐Semanaz, Elena Peeva and Elizabeth Kieras and has published in prestigious journals such as Neurology, The Lancet Neurology and Journal of Investigative Dermatology.
In The Last Decade
Matthew Scaramozza
21 papers receiving 506 citations
Peers
Matthew Scaramozza
César Álvarez-González United Kingdom
Shuji Momose Japan
Giulia Contessa Italy
Urania Vourka-Karussis Israel
Barry Turnbull United States
Rui Wu China
Zachary Spigelman United States
Shinya Rai Japan
Veronica Bernard Germany
Sophie Kaltenbach France
Citations per year, relative to Matthew Scaramozza Matthew Scaramozza (= 1×)
peers
César Álvarez-González
Countries citing papers authored by Matthew Scaramozza
Since
Specialization
Citations
This map shows the geographic impact of Matthew Scaramozza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Scaramozza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Scaramozza more than expected).
Fields of papers citing papers by Matthew Scaramozza
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Matthew Scaramozza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Scaramozza. The network helps show where Matthew Scaramozza may publish in the future.
Co-authorship network of co-authors of Matthew Scaramozza
This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Scaramozza. A scholar is included among the top collaborators of Matthew Scaramozza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Scaramozza. Matthew Scaramozza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Karatsidis, Angelos, Matthew Scaramozza, E Bartholomé, et al.. (2025). Characterizing gait in people with multiple sclerosis using digital data from smartphone sensors: A proposed framework. Multiple Sclerosis Journal. 31(5). 512–528.
2.
Scaramozza, Matthew, Patrizia A. Chiesa, Lauren Zajac, et al.. (2024). Konectom™ cognitive processing speed test enables reliable remote, unsupervised cognitive assessment in people with multiple sclerosis: Exploring the use of substitution time as a novel digital outcome measure. Multiple Sclerosis Journal. 30(9). 1193–1204.
3.
Singer, B., Sibyl Wray, Mark Gudesblatt, et al.. (2024). Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. Neurology and Therapy. 13(4). 1273–1285.
4.
Bowen, James D., et al.. (2024). Diroximel Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study. Advances in Therapy. 41(8). 3396–3406.
5.
Macdonell, Richard, et al.. (2024). Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM Study. Neurology and Therapy. 14(1). 243–260.
6.
Hunter, Samuel F., et al.. (2024). Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study. Multiple Sclerosis and Related Disorders. 91. 105912–105912.
7.
Vermersch, Patrick, Matthew Scaramozza, Raed Alroughani, et al.. (2022). Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Network Open. 5(9). e2230439–e2230439.
8.
Guo, Christine C., Ellen Cahir-McFarland, Séverine Bieuvelet, et al.. (2021). Konectom™ évaluation numérique sur smartphone des performances fonctionnelles cognitives et motrices dans la sclérose en plaques. Revue Neurologique. 177. S121–S121.
9.
Singer, B., Douglas L. Arnold, James D. Bowen, et al.. (2021). Diroximel Fumarate and Dimethyl Fumarate Demonstrate Early Radiological Efficacy in Relapsing-remitting Multiple Sclerosis (2190). Neurology. 96(15_supplement).
10.
Page, Karen, Mayte Suárez‐Fariñas, Maria Suprun, et al.. (2020). Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. Journal of Investigative Dermatology. 140(8). 1546–1555.e4.
11.
Elliott, Colm, Douglas L. Arnold, Chunlei Ke, et al.. (2020). Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. American Journal of Neuroradiology. 41(9). 1584–1591.
12.
Peeva, Elena, Elizabeth Kieras, Matthew Scaramozza, et al.. (2020). Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. The Lancet Rheumatology. 3(3). e204–e213.
13.
Gruppo, Ralph A., Daniel R Malan, J. Kapocsi, et al.. (2018). Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Journal of Thrombosis and Haemostasis. 16(10). 1984–1993.
14.
Banfield, Christopher, Matthew Scaramozza, Weidong Zhang, et al.. (2017). The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis. The Journal of Clinical Pharmacology. 58(4). 434–447.
15.
Bar‐Or, Amit, Frauke Zipp, Matthew Scaramozza, et al.. (2014). Effect of Ceralifimod (ONO-4641), a Sphingosine-1-Phosphate Receptor-1 and -5 Agonist, on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Interim Results from the Extension of the DreaMS Study (P3.161). Neurology. 82(10_supplement).
16.
Leist, Thomas, Giancarlo Comi, Bruce Cree, et al.. (2014). Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. The Lancet Neurology. 13(3). 257–267.
17.
Leist, Thomas, Gıancarlo Comı, Bruce Cree, et al.. (2013). Oral Cladribine Delays Time to Conversion to Clinically Definite MS in Patients with a First Demyelinating Event: Top Line Results from the Phase III ORACLE MS Study (P07.114). Neurology. 80(7_supplement).
18.
Montalbán, Xavier, Bruce A. Cohen, Thomas Leist, et al.. (2013). Oral Cladribine as Add on to IFN β Therapy in Patients with Active Multiple Sclerosis: Results from the Phase II ONWARD Study (P07.099). Neurology. 80(7_supplement).
19.
Giovannoni, Gavin, Gıancarlo Comı, Stuart D. Cook, et al.. (2013). Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study (P07.119). Neurology. 80(7_supplement).
20.
Comi, Giacomo P., Hans-Peter Hartung, Nuwan Kurukulasuriya, Steven J. Greenberg, & Matthew Scaramozza. (2012). Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis. Expert Opinion on Pharmacotherapy. 14(1). 123–136.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by César Álvarez-González Breakdown of academic impact, for papers by Shuji Momose Breakdown of academic impact, for papers by Giulia Contessa Breakdown of academic impact, for papers by Urania Vourka-Karussis Breakdown of academic impact, for papers by Barry Turnbull Breakdown of academic impact, for papers by Rui Wu Breakdown of academic impact, for papers by Zachary Spigelman Breakdown of academic impact, for papers by Shinya Rai Breakdown of academic impact, for papers by Veronica Bernard Breakdown of academic impact, for papers by Sophie Kaltenbach